BOUL: Revenue fell 12% amid restructuring, but operational improvements and portfolio expansion drive future growth

About this update from Boule Diagnostics Ab

2025 saw a strategic transformation with a new segment structure, cost discipline, and digitalization. Revenue declined 12%, but operational improvements and portfolio expansion position the company for future growth. Key risks include geopolitical instability and regulatory challenges. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Boule Diagnostics Ab